Close Menu

SAN FRANCISCO (GenomeWeb) – Researchers in Spain have tested the feasibility of using Illumina's TruSight One assay, which targets more than 4,800 genes associated with Mendelian disorders, as a way to screen embryos in preimplantation genetic testing for both disease-specific mutations as well as chromosomal aneuploidies in one assay.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.